GlassScriptPhysician profile
Philip S Perilstein
NPI 1841294220
$4,084.39
in general payments reported to CMS, 2019-2025
28 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $403 · 2023: $392 · 2024: $1,104 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $724.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $562.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $370.72 | 2019-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Glaxosmithkline, LLC. | $312.89 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $155.04 | 2019-2024 | Otezla, Repatha |
| Galderma Laboratories, L.P. | $142.46 | 2020 | |
| Pfizer INC. | $132.99 | 2019-2025 | |
| Janssen Biotech, INC. | $120.74 | 2024 | Tremfya |
| Exact Sciences Corporation | $108.07 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $87.43 | 2019 | |
| Intra-Sana Laboratories | $84.39 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Abbvie INC. | $83.69 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.19 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45.60 | 2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $39.35 | 2019-2024 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $29.54 | 2024 | Ingrezza |
| Amarin Pharma, INC. | $29.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.92 | 2020 | |
| Sanofi Pasteur INC. | $26.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.18 | 2019-2023 | Seglentis |
| Phathom Pharmaceuticals, INC. | $20.33 | 2024 | Voquezna |
| Bausch Health US, LLC | $19.54 | 2019 | |
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $15.92 | 2019 | |
| Allergan, INC. | $12.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Perilstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.